JO
ELTX icon

John Overdeck’s Elicio Therapeutics ELTX Stock Holding History

John Overdeck’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,073
Closed -$23K – 2626
2022
Q1 		$23K Sell
1,073
-8,321
-89% -$188K ﹤0.01% 2521
2021
Q4 		$272K Buy
+9,394
New +$475K ﹤0.01% 3705

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

John Overdeck's ELTX Position: Q2 2022 in Review

John Overdeck sold out of Elicio Therapeutics (ELTX) in Q2 2022, closing a stake of 1,073 shares — an estimated $23K sold.

John Overdeck first reported a position in ELTX in Q4 2021 and held it in 2 quarters. The position peaked at $272K in Q4 2021. 43 funds tracked by Wall St. Rank hold ELTX as of Q2 2022.

  • John Overdeck reported no remaining Elicio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • John Overdeck sold 1,073 Elicio Therapeutics shares in Q2 2022, an estimated $23K.
  • John Overdeck first reported a position in Elicio Therapeutics in Q4 2021 and held it in 2 quarters.
  • John Overdeck's Elicio Therapeutics position peaked at $272K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.